株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

バイオマーカーの世界市場の分析・予測:2019-2026年

Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy, Validation), By Application (Diagnostic, Drug Development, Personalized Medicine), By Disease, And Segment Forecasts, 2019 - 2026

発行 Grand View Research, Inc. 商品コード 823401
出版日 ページ情報 英文 103 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
バイオマーカーの世界市場の分析・予測:2019-2026年 Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy, Validation), By Application (Diagnostic, Drug Development, Personalized Medicine), By Disease, And Segment Forecasts, 2019 - 2026
出版日: 2019年04月04日 ページ情報: 英文 103 Pages
概要

世界のバイオマーカーの市場は予測期間中14.2%のCAGR (年間複合成長率) で推移し、2026年には1180億米ドルを超える規模に成長すると予測されています。技術的発展、高い消費者意識、R&D資金の拡大などの要因が同市場の成長を推進しています。

当レポートでは、世界のバイオマーカーの市場を調査し、市場および製品の概要、バリューチェーン、関連法規制、市場成長への各種影響因子の分析、バイオマーカータイプ・用途・疾患区分・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場の可変因子・動向・展望

  • 市場の展望
  • 普及・成長マッピング
  • バリューチェーン分析
  • 法規制上の枠組み
  • 市場力学
    • 成長推進因子の分析
    • 成長阻害因子の分析
  • 市場分析ツール
    • ポーターの分析
    • PESTEL分析
    • 主な提携・契約の分析

第4章 競合分析

  • 近年の展開・影響分析:主要参入事業者別
  • 企業の分類
  • ベンダー環境
  • 上場企業
  • 非上場企業

第5章 市場推計・動向分析:バイオマーカータイプ別

  • 定義・調査範囲
  • 市場シェア実績・予測
  • 市場予測・動向分析
    • 安全性
    • 有効性
    • バリデーション

第6章 市場推計・動向分析:用途別

  • 定義・調査範囲
  • 市場シェア実績・予測
  • 市場予測・動向分析
    • 診断
    • 薬剤開発
    • 個別化医療

第7章 市場推計・動向分析:疾患区分別

  • 定義・調査範囲
  • 市場シェア実績・予測
  • 市場予測・動向分析:疾患区分・バイオマーカータイプ別
    • 心血管疾患
    • 神経疾患
    • 免疫疾患
    • その他

第8章 市場推計・動向分析:地域・主要国別

  • 地域別動向
  • 主要企業
  • SWOT分析
  • 市場規模の推移・予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第9章 競合環境

  • 戦略的枠組み
  • ヒートマップ分析
  • F-Hoffman La Roche Ltd.
  • Abbott
  • Epigenomics AG
  • General Electric Company
  • Johnson & Johnson
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare Private Limited
  • Qiagen
図表

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 3 North America biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 4 North America biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 5 North America biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 6 U.S. biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 7 U.S. biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 8 U.S. biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 9 Canada biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 10 Canada biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 11 Canada biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 12 Europe biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 13 Europe biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 14 Europe biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 15 Europe biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 16 UK biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 17 UK biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 18 UK biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 19 Germany biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 20 Germany biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 21 Germany biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 13 Spain biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 14 Spain biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 15 Spain biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 16 France biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 17 France biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 18 Francebiomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 19 Italy biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 20 Italy biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 21 Italy biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 22 Asia Pacific biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 23 Asia Pacific biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 24 Asia Pacific biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 25 Asia Pacific biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 26 China biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 27 China biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 28 China biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 29 Japan biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 30 Japan biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 31 Japan biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 32 India biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 33 India biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 34 India biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 35 South Korea biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 36 South Korea biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 37 South Koreabiomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 38 Australia biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 39 Australia biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 40 Australia biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 41 Latin America biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 42 Latin America biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 43 Latin America biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 44 Latin America biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 45 Brazil biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 46 Brazil biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 47 Brazil biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 48 Mexico biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 49 Mexico biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 50 Mexico biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 51 Argentina biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 52 Argentina biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 53 Argentina biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 41 MEA biomarkers market, by country, 2014 - 2026 (USD Million)
  • TABLE 42 MEA biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 43 MEA biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 44 MEA biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 45 South Africa biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 46 South Africa biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 47 South Africa biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 48 Saudi Arabia biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 49 Saudi Arabia biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 50 Saudi Arabia biomarkers market, by disease, 2014 - 2026 (USD Million)
  • TABLE 51 UAE biomarkers market, by type, 2014 - 2026 (USD Million)
  • TABLE 52 UAE biomarkers market, by application, 2014 - 2026 (USD Million)
  • TABLE 53 UAE biomarkers market, by disease, 2014 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Value chain based sizing & forecasting
  • FIG. 4 QFD modeling for market share assessment
  • FIG. 5 Market summary
  • FIG. 6 Market trends &outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market driver relevance analysis (Current & future impact)
  • FIG. 9 Market restraint relevance analysis (Current & future impact)
  • FIG. 10 Penetration & growth prospect mapping
  • FIG. 11 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 12 Porter's Five Forces Analysis
  • FIG. 13 Biomarkers market type outlook key takeaways
  • FIG. 14 Biomarkers market: Type movement analysis
  • FIG. 15 Safety biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 16 Efficacy biomarkers market, 2014 - 2026 (USD Billion)
  • FIG. 17 Validation biomarkers market, 2014 - 2026 (USD Billion)
  • FIG. 18 Biomarkers market application outlook key takeaways
  • FIG. 19 Biomarkers market: Application movement analysis
  • FIG. 20 Diagnostics market, 2014 - 2026 (USD Million)
  • FIG. 21 Drug discovery & development market, 2014 - 2026 (USD Million)
  • FIG. 22 Personalized medicines market, 2014 - 2026 (USD Million)
  • FIG. 23 Biomarkers market disease outlook key takeaways
  • FIG. 24 Biomarkers market: Disease movement analysis
  • FIG. 25 Cancer market, 2014 - 2026 (USD Million)
  • FIG. 26 Cardiovascular market, 2014 - 2026 (USD Million)
  • FIG. 27 Neurology market, 2014 - 2026 (USD Million)
  • FIG. 28 Immunology market, 2014 - 2026 (USD Million)
  • FIG. 29 Others market, 2014 - 2026 (USD Million)
  • FIG. 30 Regional market place: Key takeaways
  • FIG. 31 Regional outlook, 2018 & 2026
  • FIG. 32 North America biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 33 U.S. biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 34 Canada biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 35 Europe biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 36 UK biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 37 Germany biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 38 France biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 39 Asia Pacific biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 40 Japan biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 41 China biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 42 India biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 43 Latin America biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 44 Brazil biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 45 Mexico biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 46 MEA biomarkers market, 2014 - 2026 (USD Million)
  • FIG. 47 South Africa biomarkers market, 2014 - 2026 (USD Million)
目次
Product Code: 978-1-68038-979-1

The global biomarkers market size is expected to reach over USD 118 billion by 2026, according to a new study by Grand View Research Inc. It is projected to expand at a CAGR of 14.2% during the forecast period. Technological advancements, high consumer awareness, and increasing funds for research and development (R&D) activities are collectively propelling the market growth.

Drug discovery was estimated to be one of the highest revenue generating segments of the market. Pharmaceutical companies are undertaking extensive R&D initiatives to develop targeted therapeutics. Coordinated research efforts on biomarker development is a rising trend among commercial R&D organizations, academic research institutions, federal government biomedical regulatory and research agencies, and nonprofitable health foundations.

North America led the biomarker market in 2018, driven by high disease prevalence, proactive governmnet initiatives, and substantial demand for personalized medicines. North America is anticipated to retain its leading position throughout the forecast period. Asia Pacific is expected to witness the fastest regional growth, spearheaded by India.

Some key players operating in the biomarkers market include F. Hoffmann-La Roche Ltd.; Abbott.; Epigenomics AG; Agilent Technologies, Inc.; Johnson & Johnson Services, Inc; Siemens Healthcare Private Limited; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; and Qiagen. Key players are developing novel kits and therapies or drugs to target population in the areas with high unmet clinical needs.

Further key findings from the study suggest:

Safety biomarkers held the largest market share of over 42% in 2018 due to reduction in drug attrition and increasing awareness of routine healthcare checkups

Validation biomarkers is estimated to be one of the fastest growing segments

Personalized medicine is estimated to grow at a CAGR of 15.0% over the forecast period owing to growing consumer awareness

Cancer held the largest market share in 2018, driven by an increase in global prevalence of cancer and the presence of a strong pipeline of drugs

Cardiovascular diseases is projected to be the fastest growing segment throughout the forecast period, supported by sedentary lifestyles and growing obese population.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & third party perspectives
    • 1.3.4. Primary research
  • 1.4. Information Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

  • 3.1. Biomarkers Market Lineage outlook
    • 3.1.1. Clinical diagnostics market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Regulatory Framework
    • 3.3.1. Reimbursement framework
    • 3.3.2. Standards & compliances
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing prevalence of chronic diseases
      • 3.4.1.2. Technological advancements
      • 3.4.1.3. Funding for biomrkers
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. Reimbursement policies
  • 3.5. Biomarkers Market Analysis Tools
    • 3.5.1. Industry analysis - Porter's
      • 3.5.1.1. Supplier power: (High due to large number of manufacturers)
      • 3.5.1.2. Buyer power: (Moderate due tolong-term contracts with manufacturers)
      • 3.5.1.3. Substitution threat: (Moderate due to no/less external substitutes)
      • 3.5.1.4. Threat from new entrant: (Moderate due to limited number of new players)
      • 3.5.1.5. Competitive rivalry: (High due to mergers & acquisitions by major players)
    • 3.5.2. PESTEL analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Environmental landscape
      • 3.5.2.3. Social landscape
      • 3.5.2.4. Technology landscape
      • 3.5.2.5. Legal landscape
    • 3.5.3. major deals & strategic alliances analysis
      • 3.5.3.1. Joint ventures
      • 3.5.3.2. Mergers & acquisitions
      • 3.5.3.3. Licensing & partnership
      • 3.5.3.4. Technology collaborations
      • 3.5.3.5. Strategic divestments

Chapter 4. Biomarkers Market - Competitive Analysis

  • 4.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 4.3. Vendor Landscape
    • 4.3.1. List of key distributors and channel partners
    • 4.3.2. Key company market share analysis, 2018
  • 4.4. Public Companies
    • 4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 4.4.2. Company Market Share
    • 4.4.3. Competitive Dashboard Analysis
    • 4.4.4. Market Differentiators
    • 4.4.5. Synergy Analysis: Major Deals & Strategic Alliances
  • 4.5. Private Companies
    • 4.5.1. List of key emerging companies
    • 4.5.2. Regional network map
    • 4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Biomarkers Market: Type Estimates & Trend Analysis

  • 5.1. Definitions & Scope
  • 5.2. Type Market Share Analysis, 2018 & 2026
  • 5.3. Biomarkers Market, by Type, 2014 to 2026
  • 5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
    • 5.4.1. Safety
      • 5.4.1.1 Safety market, 2014 - 2026 (USD Million)
    • 5.4.2. Efficacy
      • 5.4.2.1 Efficacy market, 2014 - 2026 (USD Million)
    • 5.4.3. Validation
      • 5.4.3.1 Validation market, 2014 - 2026 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Definitions & Scope
  • 6.2. Application Market Share Analysis, 2018 & 2026
  • 6.3. Biomarkers Market, by Application, 2014 to 2026
  • 6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
    • 6.4.1. Diagnostics
      • 6.4.1.1 Diagnostics market, 2014 - 2026 (USD Million)
    • 6.4.2. Drug development
      • 6.4.2.1 Drug development market, 2014 - 2026 (USD Million)
    • 6.4.3. Personalized medicine
      • 6.4.3.1 Personalized medicine market, 2014 - 2026 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

  • 7.1. Definitions & Scope
  • 7.2. Disease Market Share Analysis, 2018 & 2027
  • 7.3. Biomarkers Market, by Disease, 2014 to 2027
  • 7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2027 for the following,
    • 7.4.1. Cancer
      • 7.4.1.1 Cancer market, 2014-2027 (USD Million)
    • 7.4.2. Cardiovascular disease
      • 7.4.2.1 Cardiovascular disease market, 2014-2027 (USD Million)
    • 7.4.3. Neurological disease
      • 7.4.3.1 Neurological disease market, 2014-2027 (USD Million)
    • 7.4.4. Immunological disease
      • 7.4.4.1 Immunological disease market, 2014-2027 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1 Others market, 2014-2027 (USD Million)
  • 7.5. Disease Market, by Type, 2014 - 2026:
    • 7.5.1. Cancer
      • 7.5.1.1 Safety
      • 7.5.1.1.1 Cancer biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.1.2 Efficacy
      • 7.5.1.1.2 Cancer biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.1.3 Validation
      • 7.5.1.1.3 Cancer biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.2. Cardiovascular diseases
      • 7.5.2.1 Safety
      • 7.5.2.1.1 Cardiovascular biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.2.2 Efficacy
      • 7.5.2.1.2 Cardiovascular biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.2.3 Validation
      • 7.5.2.1.3 Cardiovascular biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.3. Neurological disease
      • 7.5.3.1 Safety
      • 7.5.3.1.1 Neurological biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.3.2 Efficacy
      • 7.5.3.1.2 Neurological biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.3.3 Validation
      • 7.5.3.1.3 Neurological biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.4. Imunological disease
      • 7.5.4.1 Safety
      • 7.5.4.1.1 Imunological biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.4.2 Efficacy
      • 7.5.4.1.2 Imunological biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.4.3 Validation
      • 7.5.4.1.3 Imunological biomarkers market, by validation, 2014 - 2026 (USD Million)
    • 7.5.5. Others
      • 7.5.5.1 Safety
      • 7.5.5.1.1 Other biomarkers market, by safety, 2014 - 2026 (USD Million)
      • 7.5.5.2 Efficacy
      • 7.5.5.1.2 Other biomarkers market, by efficacy, 2014 - 2026 (USD Million)
      • 7.5.5.3 Validation
      • 7.5.5.1.3 Other biomarkers market, by validation, 2014 - 2026 (USD Million)

Chapter 8 Biomarkers Market: Regional Estimates & Trend Analysis, by Type, Application, & Disease

  • 8.1 Biomarkers Market: Regional Movement Analysis, 2018 & 2026
  • 8.2 Biomarkers Market: Leading Players, 2018:
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa
  • 8.4 North America
    • 8.4.1 North America biomarkers market, 2014 - 2026 (USD Million)
    • 8.4.2 U.S.
      • 8.4.2.1 U.S. biomarkers market, 2014 - 2026 (USD Million)
    • 8.4.3 Canada
      • 8.4.3.1 Canada biomarkers market, 2014 - 2026 (USD Million)
  • 8.5. Europe
    • 8.5.1 Europe biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.2 UK
      • 8.5.2.1 UK biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.3 Germany
      • 8.5.3.1 Germany biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.4 Spain
      • 8.5.4.1 Spain biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.5 France
      • 8.5.5.1 France biomarkers market, 2014 - 2026 (USD Million)
    • 8.5.6 Italy
      • 8.5.6.1 Italy biomarkers market, 2014 - 2026 (USD Million)
  • 8.6 Asia Pacific
    • 8.6.1 Asia Pacific biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.2 Japan
      • 8.6.2.1 Japan biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.3 India
      • 8.6.3.1 India biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.4 South Korea
      • 8.6.4.1 South Korea biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.5 China
      • 8.6.5.1 China biomarkers market, 2014 - 2026 (USD Million)
    • 8.6.6 Australia
      • 8.6.6.1 Australia biomarkers market, 2014 - 2026 (USD Million)
  • 8.7 Latin America
    • 8.7.1 Latin America biomarkers market, 2014 - 2026 (USD Million)
    • 8.7.2 Brazil
      • 8.7.2.1 Brazil biomarkers market, 2014 - 2026 (USD Million)
    • 8.7.3 Mexico
      • 8.7.3.1 Mexico biomarkers market, 2014 - 2026 (USD Million)
    • 8.7.4 Argentina
      • 8.7.4.1 Argentina biomarkers market, 2014 - 2026 (USD Million)
  • 8.8 MEA
    • 8.8.1 MEA biomarkers market, 2014 - 2026 (USD Million)
    • 8.8.2 South Africa
      • 8.8.2.1 South Africa biomarkers market, 2014 - 2026 (USD Million)
    • 8.8.3 United Arab Emirates
      • 8.8.3.1 United Arab Emirates biomarkers market, 2014 - 2026 (USD Million)
    • 8.8.4 Saudi Arabia
      • 8.8.4.1 Saudi Arabia biomarkers market, 2014 - 2026 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Strategy Framework
  • 9.2 Heat Map Analysis of Private Companies
    • 9.2.1 Company size
    • 9.2.2 Distribution network
    • 9.2.3 Product portfolio
    • 9.2.4 Segment coverage
    • 9.2.5 Geographic presence
    • 9.2.6 Collaborations
    • 9.2.7 Conclusion
  • 9.3 F-Hoffman La Roche Ltd.
    • 9.3.1 Company overview
    • 9.3.2 Financial performance
    • 9.3.3 Product benchmarking
    • 9.3.4 Strategic initiatives
  • 9.4 Abbott
    • 9.4.1 Company overview
    • 9.4.2 Financial performance
    • 9.4.3 Product benchmarking
    • 9.4.4 Strategic initiatives
  • 9.5 Epigenomics AG
    • 9.5.1 Company overview
    • 9.5.2 Financial performance
    • 9.5.3 Product benchmarking
    • 9.5.4 Strategic initiatives
  • 9.6 General Electric Company
    • 9.6.1 Company overview
    • 9.6.2 Financial performance
    • 9.6.3 Product benchmarking
    • 9.6.4 Strategic initiatives
  • 9.7 Johnson & Johnson
    • 9.7.1 Company overview
    • 9.7.2 Financial performance
    • 9.7.3 Product benchmarking
    • 9.7.4 Strategic initiatives
  • 9.8 Thermo Fisher Scientific, Inc.
    • 9.8.1 Company overview
    • 9.8.2 Financial performance
    • 9.8.3 Product benchmarking
    • 9.8.4 Strategic initiatives
  • 9.9 Bio-Rad Laboratories, Inc.
    • 9.9.1 Company overview
    • 9.9.2 Financial performance
    • 9.9.3 Product benchmarking
    • 9.9.4 Strategic initiatives
  • 9.10 Siemens Healthcare Private Limited
    • 9.10.1 Company overview
    • 9.10.1 Financila performance
    • 9.10.2 Product benchmarking
    • 9.10.3 Strategic initiatives
  • 9.11 Qiagen
    • 9.11.1 Company Overview
    • 9.11.2 Financial performance
    • 9.11.3 Product benchmarking
    • 9.11.4 Strategic initiatives
Back to Top